---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013195"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:43:07.262080+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vaxart appoints Dr. James Breitmeyer to board of directors

## Summary
- Dr. James Breitmeyer appointed to Vaxart Board effective April 23, 2026.
- Brings over 35 years biopharma experience; led programs yielding 8 FDA product approvals.
- Currently CEO and director of Altay Therapeutics; formerly President & CEO of Oncternal Therapeutics (2016-2025).
- Prior roles include President of Bavarian Nordic (cancer/infectious disease vaccines) and senior clinical leadership at Eli Lilly and Cadence.
- Will receive standard non-employee director cash and equity compensation under Vaxart's program.

## SEC filing metadata
- accession: 0001437749-26-013195
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/0001437749-26-013195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/vxrt20260423_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013195
- JSON: https://secwatch.observer/filing/0001437749-26-013195.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.